| 1. |
- Andersson, Sören, 1957-, et al.
(författare)
-
CHIMERIC MOMP ANTIGEN
- 2015
-
Patent (populärvet., debatt m.m.)
|
|
| 2. |
- Andersson, Sören, 1957-, et al.
(författare)
-
Chimeric MOMP antigen
- 2014
-
Patent (populärvet., debatt m.m.)abstract
- The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.
|
|
| 3. |
- Lundh, Torbjörn, 1965, et al.
(författare)
-
REMOVABLE STENT AND METHOD OF PRODUCTION
- 2012
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- A removable porous stent is disclosed, which can be placed in tubular structures. It can be placed at locations, which are unsuitable for permanent stents, like across important branches in the vasculature preferably in combination with anticoagulation. The walls of the stent are freely permeable for the blood flow. A temporary stent can be used during treatment of dissections with involvement of side branches. The dissected membrane is relocated to its original place and held in place by the stent until the healing process has reattached the membrane. At this point the stent will be removed. The removable stent can also be used as a carrier of chemotherapy and/or radiation to be placed in tubular structures for local treatment of cancer. The time for treatment is controlled and finished at removal. This approach will give the possibility to increase dosages and reduce side effects. The stent is formed by at least one continuous thread arranged in interconnected loops and having a reversible bind-off at one end of the tubular body, mechanically securing each loop at said end of the tubular body apart from a single releasable loop. This loop is preferably extended beyond the tubular structure of the stent enabling an initiation of the removal at a distance from the treatment site.
|
|
| 4. |
- Seoane Martinez, Fernando, et al.
(författare)
-
Method and apparatus for brain damage detection
- 2011
-
Patent (populärvet., debatt m.m.)abstract
- The present invention comprises method and apparatus for detecting injury resulting in pathological processes affecting tissue within a portion of the body in a mammal, particularly a human brain. Said method comprises the steps of applying a first and a second pair of electrodes around the periphery of the portion, generating an alternating current at a known current level and applying said current between the first pair of electrodes, detecting and measuring the alternating voltage developed between the second pair of electrodes, and calculating the impedance of said portion. Further, the alternating current is applied between the first pair of electrodes in a series of increasing frequencies ranging within a known spectrum, and the resistance and the reactance for each frequency are detected and plotted against said frequency. The electrical impedance of said portion is calculated for each frequency and plotted into an impedance plot. Said resistance-reactance-and impedance-plots are finally analyzed, and any notable changes compared to normal spectrum profiles and plots are detected and evaluated.
|
|
| 5. |
- Härd, Torleif
(författare)
-
Stable amyloid beta monomers and oligomers
- 2009
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
|
|
| 6. |
- Johansson, Jan, et al.
(författare)
-
Method of producing polymers of spider silk proteins
- 2012
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- Amethodofproducingpolymersofan isolatedspidersilkprotein consistingoffrom 170 to 600 amino acid residues involves providing a solutionofsaidspidersilkprotein in a liquid medium at pH 6.4 or higher and/or an ion composition that prevents polymerisationofthespidersilkprotein. The propertiesofthe liquid medium are adjusted to a pHof6.3 or lower and an ion composition that allows polymerisationofthespidersilkprotein. Thespidersilkprotein is allowed to form solidpolymersin the liquid medium, and the resulting solidspidersilkproteinpolymersare isolated from the liquid medium. The resultingpolymersare useful as fibers, films, foams, nets or meshes.
|
|
| 7. |
- Johansson, Jan, et al.
(författare)
-
Spider silk proteins and methods for producing spider silk proteins
- 2012
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
|
|
| 8. |
|
|
| 9. |
- Nilsson, Peter, et al.
(författare)
-
Biomarker of renal impairment
- 2011
-
Patent (populärvet., debatt m.m.)abstract
- There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the previous sample value, c2) concluding that the subject belongs to the second group. Associated means are also provided.
|
|
| 10. |
- Nilsson, Peter, et al.
(författare)
-
Prostate cancer biomarkers
- 2010
-
Patent (populärvet., debatt m.m.)abstract
- The present disclosure relates to a method of determining whether a mammalian subject belongs to a first or a second group of subjects, wherein the risk of having a prostate cancer, such as an aggressive prostate cancer, is higher in the first group than in the second group. The method comprises the steps of: a) evaluating an amount of unglycosylated CNDP1 protein in a sample derived from blood, semen or urine from the subject and determining a sample value corresponding to the evaluated amount; b) comparing the sample value with a predetermined reference value; and if the sample value is lower than or equal to the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is higher than the reference value, c2) concluding that the subject belongs to the second group. Further, the present disclosure relates to a similar method based on the protein HCRTR1 as well as corresponding uses and means useful when carrying out the methods.
|
|
